Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingzhi Fuzheng Granules maintenance therapy in advanced non-small cell lung cancer
CTR20160070Phase 2Active
- Sponsor
- Shenyang Wanjia Biotechnology Research Institute
- Start
- Apr 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lingzhi fuzheng granules in non-small cell lung cancer (NSCLC), sponsored by Shenyang Wanjia Biotechnology Research Institute. Started Apr 2017; status: active.
02
Drugs
lingzhi fuzheng granules
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160070.